NCT00782080 is a Phase 3 clinical trial of Sedariston in ADHD, sponsored by Prof. Huss.

Who is sponsoring NCT00782080?

NCT00782080 is sponsored by Prof. Huss.

What drugs are being tested in NCT00782080?

Interventions in NCT00782080: Sedariston, Placebo.

Is NCT00782080 still recruiting?

NCT00782080 is currently completed. Last updated 12 March 2014.

Last reviewed 2014-03-12 · How we verify

NCT00782080

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) Versus Placebo in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD)

Completed Phase 3 Last updated 12 March 2014

What this trial tests

Phase 3 trial testing Sedariston in ADHD in 155 participants. Completed in 1 June 2010.

Timeline

1 July 2008

Primary endpoint
1 March 2010

1 June 2010

Quick facts

Lead sponsor	Prof. Huss
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	155
Start date	1 July 2008
Primary completion	1 March 2010
Estimated completion	1 June 2010
Sites	5 locations across Germany

Drugs / interventions tested

Sedariston — full drug profile →
Placebo

Conditions studied

ADHD — all drugs for ADHD →

Sponsor

Prof. Huss

Who can join

Adults 6 to 17, any sex, with ADHD. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

ADHD-IV rating scale
Time frame: Difference in total score between baseline and end of study

Sponsor's own description

This study will determine the safety and efficacy of an herbal treatment in children and adolescents with ADHD. Study Design: * Randomized * Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) * Placebo Control * Parallel Assignment

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Enhancing of cerebral Abeta clearance by modulation of ABC transporter expression: a review of experimental approaches.
Loeffler DA. · · 2024 · cited 2× · PMID 38872626 · DOI 10.3389/fnagi.2024.1368200

Verify or expand the search:

Other recruiting trials for ADHD

Currently open trials in the same condition.

NCT07314333 — A Trial to Assess How Centanafadine Interacts With Stimulants in the Body · Phase 1 · recruiting
NCT07262853 — Dual Executive Function Training Package · NA · recruiting
NCT07291453 — Loving Habits: A Feasibility Study of a Support Program for Building New Parent-child Behavioral Habits · NA · recruiting
NCT07281092 — Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) · NA · recruiting
NCT07219810 — Accelerated iTBS Targeting of Working Memory Versus Inhibitory Control in Adolescent ADHD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00782080 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Huss
Last refreshed: 12 March 2014

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00782080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing